Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))

The authors regret that Section 3.9, paragraph, In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break, and efficacy was defined as 1-yr PFS of 70%. Patients received SABR for all lesions and were maintained off systemic therapy. While the efficacy objective was not met, at a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events should read as follows: “In a prospective phase II clinical trial, Tang et al. [35] evaluated the feasibility and efficacy of definitive intent radiotherapy in 30 mRCC patients with fewer than six lesions. Feasibility was defined as completion of SABR with <7 d of unplanned break. Patients received SABR for all lesions and were maintained off systemic therapy. At a median follow-up of 17.5 mo, the trial demonstrated impressive 1-yr PFS and systemic therapy–free survival of 64% and 82%, respectively, with two grade 3 and one grade 4 (hyperglycaemia) adverse events” Table 1 row (Correa et al.) column (Dose (Gy)/fraction) should read 26/1, 30–40/3–5. The authors would like to apologise for any inconvenience caused.